Detection of aberrant methylation of p16, DAP kinase, GSTP1, and MGMT in serum and tumor DNA from lung cancer patientsa
| Patient no. . | Tumor DNA/Serum DNA . | . | . | . | Stage (TNM) . | Histology . | Follow-upb . | Outcomeb . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | p16 . | DAP . | GSTP1 . | MGMT . | . | . | . | . | |||
| 1 | U/U | M/M | U/U | U/U | IIIA (T2N2M0) | SCC | 15 metbone | 17.DOD | |||
| 42 | M/U | U/U | U/U | U/U | IIIA (T1N2M0) | SCC | 22 metlung | 29+.AWD | |||
| 52 | M/U | U/U | M/M | U/U | II (T1N1M0) | SCC | 27+ | 27+.NED | |||
| 63 | M/M | U/U | U/U | U/U | I (T2N0M0) | SCC | 25+ | 25+.NED | |||
| 64 | M/U | M/M | U/U | M/U | II (T2N1M0) | SCC | 25+ | 25+.NED | |||
| 68 | M/U | U/U | U/U | U/U | IIIA (T3N0M0) | AC | 8 | 10.DOD | |||
| 76 | U/U | U/U | U/U | M/M | I (T2N0M0) | SCC | 26+ | 26+.NED | |||
| 78 | M/M | U/U | U/U | M/M | I (T2N0M0) | SCC | 6 metlung | 24.DOD | |||
| 83 | U/U | U/U | U/U | M/M | I (T2N0M0) | SCC | 23+ | 23+.NED | |||
| 84 | U/U | M/M | M/U | U/U | I (T2N0M0) | AC | LTF | ||||
| 94 | M/M | U/U | U/U | U/U | IIIA (T3N0M0) | SCC | 15 metbone | 19+.AWD | |||
| 95 | M/U | U/U | U/U | U/U | IIIA (T2N2M0) | AC | 5 metbrain | 22.DOD | |||
| 98 | U/U | U/U | U/U | M/M | I (T2N0M0) | AC | 21+ | 21+.NED | |||
| 106 | U/U | M/U | U/U | U/U | I (T2N0M0) | LCC | LTF | ||||
| 112 | M/U | M/M | U/U | M/U | II (T1N1M0) | SCC | 19+ | 19+.NED | |||
| 36 | U/U | U/U | U/U | U/U | IIIA (T3N0M0) | AC | 12 metbone | 16.DOD | |||
| 49 | U/U | U/U | U/U | U/U | IIIA (T3N2M0) | SCC | 11 metbone | 31+.AWD | |||
| 66 | U/U | U/U | U/U | U/U | I (T2N0M0) | bAC | 9 metlung | 18+.DOD | |||
| 74 | U/U | U/U | U/U | U/U | I (T2N0M0) | SCC | 12 metliver | 14.DOD | |||
| 80 | U/U | U/U | U/U | U/U | IV (T1N2M1) | AC | 6 metbone | 8.DOD | |||
| 108 | U/U | U/U | U/U | U/U | I (T2N0M0) | SCC | 2 metbone | 3.DOD | |||
| 110 | U/U | U/U | U/U | U/U | IIIA (T1N2M0) | SCC | 8 metlung | 24+.AWD | |||
| Patient no. . | Tumor DNA/Serum DNA . | . | . | . | Stage (TNM) . | Histology . | Follow-upb . | Outcomeb . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|
| . | p16 . | DAP . | GSTP1 . | MGMT . | . | . | . | . | |||
| 1 | U/U | M/M | U/U | U/U | IIIA (T2N2M0) | SCC | 15 metbone | 17.DOD | |||
| 42 | M/U | U/U | U/U | U/U | IIIA (T1N2M0) | SCC | 22 metlung | 29+.AWD | |||
| 52 | M/U | U/U | M/M | U/U | II (T1N1M0) | SCC | 27+ | 27+.NED | |||
| 63 | M/M | U/U | U/U | U/U | I (T2N0M0) | SCC | 25+ | 25+.NED | |||
| 64 | M/U | M/M | U/U | M/U | II (T2N1M0) | SCC | 25+ | 25+.NED | |||
| 68 | M/U | U/U | U/U | U/U | IIIA (T3N0M0) | AC | 8 | 10.DOD | |||
| 76 | U/U | U/U | U/U | M/M | I (T2N0M0) | SCC | 26+ | 26+.NED | |||
| 78 | M/M | U/U | U/U | M/M | I (T2N0M0) | SCC | 6 metlung | 24.DOD | |||
| 83 | U/U | U/U | U/U | M/M | I (T2N0M0) | SCC | 23+ | 23+.NED | |||
| 84 | U/U | M/M | M/U | U/U | I (T2N0M0) | AC | LTF | ||||
| 94 | M/M | U/U | U/U | U/U | IIIA (T3N0M0) | SCC | 15 metbone | 19+.AWD | |||
| 95 | M/U | U/U | U/U | U/U | IIIA (T2N2M0) | AC | 5 metbrain | 22.DOD | |||
| 98 | U/U | U/U | U/U | M/M | I (T2N0M0) | AC | 21+ | 21+.NED | |||
| 106 | U/U | M/U | U/U | U/U | I (T2N0M0) | LCC | LTF | ||||
| 112 | M/U | M/M | U/U | M/U | II (T1N1M0) | SCC | 19+ | 19+.NED | |||
| 36 | U/U | U/U | U/U | U/U | IIIA (T3N0M0) | AC | 12 metbone | 16.DOD | |||
| 49 | U/U | U/U | U/U | U/U | IIIA (T3N2M0) | SCC | 11 metbone | 31+.AWD | |||
| 66 | U/U | U/U | U/U | U/U | I (T2N0M0) | bAC | 9 metlung | 18+.DOD | |||
| 74 | U/U | U/U | U/U | U/U | I (T2N0M0) | SCC | 12 metliver | 14.DOD | |||
| 80 | U/U | U/U | U/U | U/U | IV (T1N2M1) | AC | 6 metbone | 8.DOD | |||
| 108 | U/U | U/U | U/U | U/U | I (T2N0M0) | SCC | 2 metbone | 3.DOD | |||
| 110 | U/U | U/U | U/U | U/U | IIIA (T1N2M0) | SCC | 8 metlung | 24+.AWD | |||
TNM, tumor-node-metastasis; M, methylated; U, unmethylated; SCC, squamous cell carcinoma; AC, adenocarcinoma; bAC, bronchoalveolar adenocarcinoma; LCC, large cell carcinoma; metbone, bone metastasis; metbrain, brain metastasis; metliver, metastasis; metlung, lung metastasis; +, alive; AWD, alive with disease; DOD, died of disease; LTF, lost to follow-up; NED, no evidence of disease.
The follow-up and outcome are indicated in months.